Nonsteroidal Anti-inflammatory Drugs in Ophthalmology
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed in ophthalmology to reduce miosis and inflammation, manage scleritis, and prevent and treat cystoid macular edema associated with cataract surgery. In addition, they may decrease postoperative pain and photophobia associated with refractive surgery and may reduce the itching associated with allergic conjunctivitis. In recent years, the U.S. Food and Drug Administration has approved new topical NSAIDs, and previously approved NSAIDs have been reformulated. These additions and changes result in different pharmacokinetics and dosing intervals, which may offer therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide an updated review on NSAIDs and a summary of their current uses in ophthalmology with attention to potential future applications.
1Department of Ophthalmology, Vanderbilt University, Nashville, Tennessee, USA
2Department of Ophthalmology, University of California and Veterans Administration, San Francisco, California, USA
3Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Reprint address: Steven J Kim, MD, Vanderbilt University, Ophthalmology, 2311 Pierce Avenue, Nashville, TN 37232, United States.
The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Supported in part by unrestrictive grants from Research to Prevent Blindness, Inc, New York, New York (Drs. Jampol and Flach) and That Man May See, San Francisco, California (Dr. Flach). The authors would like to acknowledge the contributions of Dr. Hassanain S. Toma who assisted in preparation of this manuscript.
ABSTRACT